JP2008534454A - 嘔吐のためのnk−1アンタゴニストの代謝物 - Google Patents
嘔吐のためのnk−1アンタゴニストの代謝物 Download PDFInfo
- Publication number
- JP2008534454A JP2008534454A JP2008502283A JP2008502283A JP2008534454A JP 2008534454 A JP2008534454 A JP 2008534454A JP 2008502283 A JP2008502283 A JP 2008502283A JP 2008502283 A JP2008502283 A JP 2008502283A JP 2008534454 A JP2008534454 A JP 2008534454A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- compound
- disease
- piperazin
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C)(*(N(C)c(cnc(N(CC1)CC[N+]1(C)O)c1)c1-c1c(C)cccc1)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 Chemical compound CC(C)(*(N(C)c(cnc(N(CC1)CC[N+]1(C)O)c1)c1-c1c(C)cccc1)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 0.000 description 1
- WAXQNWCZJDTGBU-UHFFFAOYSA-N CC(C)(C(N(C)c(c(-c1c(C)cccc1)c1)cnc1N1CCN(C)CC1)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 Chemical compound CC(C)(C(N(C)c(c(-c1c(C)cccc1)c1)cnc1N1CCN(C)CC1)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 WAXQNWCZJDTGBU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
(式中、
Rは、メチルであり;そして
R1は、4−メチル−4−オキシ−ピペラジン−1−イルであるか;又は
Rは、CH2OHであり、そして
R1は、4−メチル−ピペラジン−1−イル又は4−メチル−4−オキシ−ピペラジン−1−イルである)
の化合物及びその薬学的に許容される酸付加塩に関する。
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−[4−(2−ヒドロキシメチル−フェニル)−6−(4−メチル−ピペラジン−1−イル)−ピリジン−3−イル]−N−メチル−イソブチルアミド(化合物I−2)及び、
2−(3,5−ジメチル−フェニル)−N−[4−(2−ヒドロキシメチル−フェニル)−6−(4−メチル−4−オキシ−ピペラジン−1−イル)−ピリジン−3−イル]−N−メチル−イソブチルアミド(1−3)、
を含む式Iの化合物及びその薬学的に許容される塩、上記化合物の製造、それらを含有する医薬及びその製造、並びに、疾病、特に、前記で言及された種類の疾病及び障害の抑制若しくは予防における又は対応する薬剤の製造における上記化合物の使用である。
a)式
b)式
DIPEA N−エチルジイソプロピル−アミン
KHMDS カリウム ヘキサメチルジシラジド
平衡溶解度の方法説明
方法説明:
浸透度を、96ウェルマイクロプレートに基づくPAMPA PSR4pアッセイにより調査した。浸透度を「サンドイッチ」構造を用いて測定する。フィルタープレートをリン脂質(膜)でコーティングし、薬物/緩衝溶液を含むドナープレート中に配置する。最後に、フィルタープレートに緩衝溶液(アクセプタ)を充填する。ドナー濃度を、t−start時(参考)に測定し、特定時間のt−end後のドナー及びアクセプタ濃度と比較する。以下のセットアップをPAMPA PSR4pアッセイに使用する:
膜:ドデカン中、10%(w/v)卵レシチン+0.5%(w/v)コレステロール
アクセプタ:pH6.5の0.05 MOPSO緩衝液
以下の組成の錠剤を常法により製造する:
mg/錠剤
活性物質 5
乳糖 45
トウモロコシデンプン 15
微晶質セルロース 34
ステアリン酸マグネシウム 1
錠剤重量 100
以下の組成のカプセル剤を常法により製造する:
mg/カプセル剤
活性物質 10
乳糖 155
トウモロコシデンプン 30
タルク 5
カプセル充填重量 200
以下の組成の座剤を製造する:
mg/座剤
活性物質 15
座薬用錬剤 1285
総量 1300
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−メチル−N−[6−(4−メチル−4−オキシ−ピペラジン−1−イル)−4−o−トリル−ピリジン−3−イル]−イソブチルアミド(化合物I−1)
MS m/e(%):595(M+H+、100)
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−[4−(2−ヒドロキシメチル−フェニル)−6−(4−メチル−ピペラジン−1−イル)−ピリジン−3−イル]−N−メチル−イソブチルアミド(化合物I−2)
3N塩酸50ml中のN−[4−ヨード−6−(4−メチル−ピペラジン−1−イル)−ピリジン−3−イル]−2,2−ジメチル−プロピオンアミド(合成はDE10008042に記載されている)2.20g(5.47mmol)の混合物を、100℃で18時間撹拌した。0℃まで冷却した後、反応混合物をエーテル(50ml)で2回洗浄した。水相をジクロロメタン50mlで処理し、炭酸ナトリウムの1M溶液で塩基性化した。有機相を分離し、水相をジクロロメタン50mlで4回抽出した。合わせた有機層を硫酸ナトリウムで乾燥し、真空下で濃縮して、標記化合物1.60g(92%)をオフホワイトの固体として得た。
MS m/e(%):319(M+H+、100)
ジクロロメタン16ml中の、4−ヨード−6−(4−メチル−ピペラジン−1−イル)−ピリジン−3−イルアミン1.60g(5.03mmol)及びN,N−ジイソプロピルエチルアミン975mg(7.54mmol)の懸濁液に、2−(3,5−ビス−トリフルオロメチル−フェニル)−2−メチル−プロピオニル クロライド1.76g(5.53mmol)を0℃で滴下した。反応混合物を室温で2時間及び還流温度で2時間撹拌した。室温まで冷却した後、反応混合物を1M炭酸ナトリウム水溶液20ml及び水20mlで洗浄した。合わせた有機層を硫酸ナトリウムで乾燥し、真空下で濃縮して、粗標記化合物3.39g(100%)を褐色の油状物として得た。
MS m/e(%):601(M+H+、100)
N,N−ジメチルホルムアミド30ml中の2−(3,5−ビス−トリフルオロメチル−フェニル)−N−[4−ヨード−6−(4−メチル−ピペラジン−1−イル)−ピリジン−3−イル]−イソブチルアミド3.09g(5.15mmol)の溶液に、テトラヒドロフラン中のカリウム ビス(トリメチルシリル)アミドの0.91M溶液6.8ml(6.2mmol)を0℃で加えた。0℃で40分間撹拌した後、ヨードメタン0.352ml(5.66mmol)を加えた。混合物を密閉したフラスコ内で2日間撹拌した。反応混合物を真空下で濃縮し、フラッシュクロマトグラフィーにより精製して、標記化合物980mg(31%)を褐色の油状物として得た。
MS m/e(%):615(M+H+、100)
ジメトキシエタン5ml中の、2−(3,5−ビス−トリフルオロメチル−フェニル)−N−[4−ヨード−6−(4−メチル−ピペラジン−1−イル)−ピリジン−3−イル]−N−メチル−イソブチルアミド900mg(1.47mmol)、1M炭酸ナトリウム水溶液2.8ml、酢酸パラジウム(II)33mg(0.15mmol)、トリフェニルホスフィン77mg(0.29mmol)及び2−ホルミルフェニルボロン酸242mg(1.61mmol)の混合物を排気させ、アルゴンを充填し、80℃で2時間撹拌した。室温まで冷却した後、反応混合物を酢酸エチル20mlで希釈し、ブライン20mlで洗浄した。合わせた有機層を硫酸ナトリウムで乾燥し、濃縮し、フラッシュクロマトグラフィーにより精製して、標記化合物584mg(67%)を淡褐色の固体として得た。
MS m/e(%):593(M+H+、100)
メタノール2ml中の水素化ホウ素ナトリウム15mg(0.41mmol)の混合物に、2−(3,5−ビス−トリフルオロメチル−フェニル)−N−[4−(2−ホルミル−フェニル)−6−(4−メチル−ピペラジン−1−イル)−ピリジン−3−イル]−N−メチル−イソブチルアミド200mg(0.338mmol)を0℃で加えた。0℃で1時間撹拌した後、ブライン1mlを0℃で加えた。混合物を30分間撹拌した。メタノールを留去し、残渣を酢酸エチル20mlで希釈し、ブライン20mlで洗浄した。有機層を硫酸ナトリウムで乾燥し、濃縮し、フラッシュクロマトグラフィーにより精製して、標記化合物137mg(68%)を淡褐色の固体として得た。
MS m/e(%):595(M+H+、100)
Claims (12)
- 2−(3,5−ビス−トリフルオロメチル−フェニル)−N−メチル−N−[6−(4−メチル−4−オキシ−ピペラジン−1−イル)−4−o−トリル−ピリジン−3−イル]−イソブチルアミド(化合物I−1)又は、
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−[4−(2−ヒドロキシメチル−フェニル)−6−(4−メチル−ピペラジン−1−イル)−ピリジン−3−イル]−N−メチル−イソブチルアミド(化合物I−2)である、請求項1記載の化合物。 - 請求項1又は2記載の一種以上の化合物及び薬学的に許容される賦形剤を含む医薬。
- NK−1レセプターアンタゴニストに関する疾患を処置するための、請求項3記載の医薬。
- 片頭痛、関節リウマチ及び喘息を含む炎症状態、嘔吐、パーキンソン病、疼痛、頭痛、特に片頭痛、アルツハイマー病、不安、鬱病、多発性硬化症、モルヒネ禁断の減衰、心血管変化、浮腫、アレルギー性鼻炎、クローン病、精神病、乗り物酔い及び嘔吐を処置するための、請求項3及び4記載の医薬。
- 請求項6記載の方法又は同等の方法のいずれかにより製造される、請求項1又は2記載の化合物。
- NK−1レセプターアンタゴニストに関連する疾患を処置するための、請求項1又は2記載の化合物の使用。
- NK−1レセプターアンタゴニストに関連する疾患を処置する医薬を製造するための、請求項1又は2記載の化合物の使用。
- 片頭痛、関節リウマチ及び喘息を含む炎症状態、嘔吐、パーキンソン病、疼痛、頭痛、特に片頭痛、アルツハイマー病、不安、鬱病、多発性硬化症、モルヒネ禁断の減衰、心血管変化、浮腫、アレルギー性鼻炎、クローン病、精神病、乗り物酔い及び嘔吐を処置する医薬を製造するための、請求項1又は2記載の化合物の使用。
- 嘔吐を処置する医薬を製造するための、請求項1又は2記載の化合物の使用。
- 本明細書記載の発明。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05102359 | 2005-03-23 | ||
EP05102359.6 | 2005-03-23 | ||
PCT/EP2006/002313 WO2006099968A1 (en) | 2005-03-23 | 2006-03-14 | Metabolites for nk-i antagonists for emesis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008534454A true JP2008534454A (ja) | 2008-08-28 |
JP4768010B2 JP4768010B2 (ja) | 2011-09-07 |
Family
ID=36587133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008502283A Expired - Fee Related JP4768010B2 (ja) | 2005-03-23 | 2006-03-14 | 嘔吐のためのnk−1アンタゴニストの代謝物 |
Country Status (22)
Country | Link |
---|---|
US (1) | US7211579B2 (ja) |
EP (1) | EP1863767B1 (ja) |
JP (1) | JP4768010B2 (ja) |
KR (1) | KR100903224B1 (ja) |
CN (1) | CN101146775B (ja) |
AR (1) | AR052949A1 (ja) |
AT (1) | ATE425144T1 (ja) |
AU (1) | AU2006226665B2 (ja) |
BR (1) | BRPI0609699A2 (ja) |
CA (1) | CA2602445C (ja) |
DE (1) | DE602006005624D1 (ja) |
DK (1) | DK1863767T3 (ja) |
ES (1) | ES2320590T3 (ja) |
IL (1) | IL185689A (ja) |
MX (1) | MX2007011489A (ja) |
NO (1) | NO20074622L (ja) |
PL (1) | PL1863767T3 (ja) |
PT (1) | PT1863767E (ja) |
RU (1) | RU2404969C2 (ja) |
TW (1) | TWI316056B (ja) |
WO (1) | WO2006099968A1 (ja) |
ZA (1) | ZA200708029B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014507446A (ja) * | 2011-11-29 | 2014-03-27 | ヘルシン ヘルスケア ソシエテ アノニム | Nk−1レセプター関連疾患の治療のための置換4−フェニル−ピリジン |
US9403772B2 (en) | 2011-11-29 | 2016-08-02 | Helsinn Healthcare Sa | 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1984891B (zh) | 2004-07-06 | 2012-08-08 | 弗·哈夫曼-拉罗切有限公司 | 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法 |
CA2930008A1 (en) | 2013-11-08 | 2015-05-14 | Kissei Pharmaceutical Co., Ltd. | Carboxymethyl piperidine derivative |
US20150315149A1 (en) * | 2014-05-05 | 2015-11-05 | Apicore Us Llc | Methods of making netupitant and intermediates thereof |
TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
CN112174881B (zh) * | 2019-07-04 | 2022-06-21 | 上海森辉医药有限公司 | 一种奈妥匹坦的衍生物及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1035115A1 (en) * | 1999-02-24 | 2000-09-13 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
JP2001151754A (ja) * | 1999-11-29 | 2001-06-05 | F Hoffmann La Roche Ag | 2−(3,5−ビス−トリフルオロメチル−フェニル)−N−メチル−N−(6−モルホリン−4−イル−4−o−トリル−ピリジン−3−イル)−イソブチルアミド |
JP2004504301A (ja) * | 2000-07-14 | 2004-02-12 | エフ.ホフマン−ラ ロシュ アーゲー | Nk1受容体拮抗物質プロドラッグとしての4−フェニル−ピリジン誘導体のn−オキシド |
JP2004536119A (ja) * | 2001-07-10 | 2004-12-02 | エフ.ホフマン−ラ ロシュ アーゲー | 脳、脊髄又は神経損傷の処置のためのnk−1レセプターアンタゴニストの使用 |
WO2005002577A1 (en) * | 2003-07-03 | 2005-01-13 | F. Hoffmann-La Roche Ag | Dual nk1/nk3 antagonists for treating schizophrenia |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4745123A (en) | 1986-02-18 | 1988-05-17 | Warner-Lambert Company | Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents |
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
SG52217A1 (en) | 1993-12-29 | 1998-09-28 | Merck Sharp & Dohme | Substituted morpholine derivatives and their use as therapeutic agents |
IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
US6479482B2 (en) * | 2000-05-10 | 2002-11-12 | Bristol-Myers Squibb Company | Alkylamine derivatives of dihydropyridine NPY antagonists |
-
2006
- 2006-03-14 CN CN2006800094426A patent/CN101146775B/zh active Active
- 2006-03-14 BR BRPI0609699-9A patent/BRPI0609699A2/pt not_active IP Right Cessation
- 2006-03-14 DK DK06707550T patent/DK1863767T3/da active
- 2006-03-14 ES ES06707550T patent/ES2320590T3/es active Active
- 2006-03-14 PT PT06707550T patent/PT1863767E/pt unknown
- 2006-03-14 MX MX2007011489A patent/MX2007011489A/es active IP Right Grant
- 2006-03-14 WO PCT/EP2006/002313 patent/WO2006099968A1/en active Application Filing
- 2006-03-14 JP JP2008502283A patent/JP4768010B2/ja not_active Expired - Fee Related
- 2006-03-14 AT AT06707550T patent/ATE425144T1/de active
- 2006-03-14 CA CA2602445A patent/CA2602445C/en not_active Expired - Fee Related
- 2006-03-14 EP EP06707550A patent/EP1863767B1/en active Active
- 2006-03-14 KR KR1020077021748A patent/KR100903224B1/ko active IP Right Grant
- 2006-03-14 DE DE602006005624T patent/DE602006005624D1/de active Active
- 2006-03-14 AU AU2006226665A patent/AU2006226665B2/en not_active Ceased
- 2006-03-14 RU RU2007134901/04A patent/RU2404969C2/ru not_active IP Right Cessation
- 2006-03-14 PL PL06707550T patent/PL1863767T3/pl unknown
- 2006-03-15 US US11/376,042 patent/US7211579B2/en active Active
- 2006-03-20 TW TW095109514A patent/TWI316056B/zh not_active IP Right Cessation
- 2006-03-21 AR ARP060101093A patent/AR052949A1/es unknown
-
2007
- 2007-09-03 IL IL185689A patent/IL185689A/en not_active IP Right Cessation
- 2007-09-12 NO NO20074622A patent/NO20074622L/no not_active Application Discontinuation
- 2007-09-18 ZA ZA200708029A patent/ZA200708029B/xx unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1035115A1 (en) * | 1999-02-24 | 2000-09-13 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
JP2001151754A (ja) * | 1999-11-29 | 2001-06-05 | F Hoffmann La Roche Ag | 2−(3,5−ビス−トリフルオロメチル−フェニル)−N−メチル−N−(6−モルホリン−4−イル−4−o−トリル−ピリジン−3−イル)−イソブチルアミド |
JP2004504301A (ja) * | 2000-07-14 | 2004-02-12 | エフ.ホフマン−ラ ロシュ アーゲー | Nk1受容体拮抗物質プロドラッグとしての4−フェニル−ピリジン誘導体のn−オキシド |
JP2004536119A (ja) * | 2001-07-10 | 2004-12-02 | エフ.ホフマン−ラ ロシュ アーゲー | 脳、脊髄又は神経損傷の処置のためのnk−1レセプターアンタゴニストの使用 |
WO2005002577A1 (en) * | 2003-07-03 | 2005-01-13 | F. Hoffmann-La Roche Ag | Dual nk1/nk3 antagonists for treating schizophrenia |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014507446A (ja) * | 2011-11-29 | 2014-03-27 | ヘルシン ヘルスケア ソシエテ アノニム | Nk−1レセプター関連疾患の治療のための置換4−フェニル−ピリジン |
JP2015017121A (ja) * | 2011-11-29 | 2015-01-29 | ヘルシン ヘルスケア ソシエテ アノニム | Nk−1レセプター関連疾患の治療のための置換4−フェニル−ピリジン |
US9403772B2 (en) | 2011-11-29 | 2016-08-02 | Helsinn Healthcare Sa | 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator |
US9908907B2 (en) | 2011-11-29 | 2018-03-06 | Helsinn Healthcare Sa | Substituted piperaziniums for the treatment of emesis |
US10208073B2 (en) | 2011-11-29 | 2019-02-19 | Helsinn Healthcare Sa | Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator |
US10717721B2 (en) | 2011-11-29 | 2020-07-21 | Helsinn Healthcare Sa | Substituted piperaziniums for the treatment of emesis |
US11312698B2 (en) | 2011-11-29 | 2022-04-26 | Helsinn Healthcare Sa | Fosnetupitant chloride hydrochloride having improved stability |
US12071421B2 (en) | 2011-11-29 | 2024-08-27 | Helsinn Healthcare Sa | Process for the synthesis of substituted chloromethyl dialkylphosphates |
Also Published As
Publication number | Publication date |
---|---|
JP4768010B2 (ja) | 2011-09-07 |
KR100903224B1 (ko) | 2009-06-17 |
PT1863767E (pt) | 2009-03-27 |
MX2007011489A (es) | 2007-10-11 |
BRPI0609699A2 (pt) | 2010-04-20 |
EP1863767B1 (en) | 2009-03-11 |
IL185689A0 (en) | 2008-01-06 |
CA2602445A1 (en) | 2006-09-28 |
AU2006226665A1 (en) | 2006-09-28 |
WO2006099968A1 (en) | 2006-09-28 |
CN101146775A (zh) | 2008-03-19 |
AU2006226665B2 (en) | 2011-01-27 |
ATE425144T1 (de) | 2009-03-15 |
TWI316056B (en) | 2009-10-21 |
CN101146775B (zh) | 2012-07-18 |
TW200700390A (en) | 2007-01-01 |
US7211579B2 (en) | 2007-05-01 |
RU2007134901A (ru) | 2009-04-27 |
NO20074622L (no) | 2007-10-18 |
PL1863767T3 (pl) | 2009-08-31 |
DE602006005624D1 (de) | 2009-04-23 |
ZA200708029B (en) | 2008-11-26 |
AR052949A1 (es) | 2007-04-11 |
US20060217393A1 (en) | 2006-09-28 |
EP1863767A1 (en) | 2007-12-12 |
DK1863767T3 (da) | 2009-05-04 |
CA2602445C (en) | 2013-08-20 |
RU2404969C2 (ru) | 2010-11-27 |
IL185689A (en) | 2012-05-31 |
KR20070107146A (ko) | 2007-11-06 |
ES2320590T3 (es) | 2009-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3399900B2 (ja) | 4−フェニル−ピリジン誘導体 | |
JP3950044B2 (ja) | Nk1受容体拮抗物質プロドラッグとしての4−フェニル−ピリジン誘導体のn−オキシド | |
JP4118673B2 (ja) | ニューロキニン1受容体アンタゴニストとしての4−フェニル−ピリジン誘導体 | |
JP4768010B2 (ja) | 嘔吐のためのnk−1アンタゴニストの代謝物 | |
JP3480835B2 (ja) | 2−(3,5−ビス−トリフルオロメチル−フェニル)−N−メチル−N−(6−モルホリン−4−イル−4−o−トリル−ピリジン−3−イル)−イソブチルアミド | |
JP4700908B2 (ja) | 2−(3,5−ビス−トリフルオロメチル−フェニル)−N−〔6−(1,1−ジオキソ−1λ6−チオモルホリン−4−イル)−4−(2−メチル又は4−フルオロ−2−メチル置換)フェニル−ピリジン−3−イル〕−N−メチル−イソブチルアミド | |
JP4767973B2 (ja) | Nk1アンタゴニスト |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101207 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110307 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110308 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110314 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110531 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110615 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4768010 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140624 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |